Table 3.
Study characteristics of 18F-PSMA PET/CT.
| Author | Publication Year | Country | Design | Patients | Mean age/year | PSA (ng/ml) | Scancer Modality | Tracer | Mean dose | Reference standard |
|---|---|---|---|---|---|---|---|---|---|---|
| Rahbar | 2018 | Germany | R | 100 | 68.75 ± 7.6 | 3.3 6 ± 6.11 | Siemens Healthcare | 18F-PSMA-1007 | 4 MBq/kg | —— |
| Eiber | 2018 | Germany | R | 261 | 72 (49–88) | 0.961 (0.01–400.0) | Siemens Biograph mCT | 18F‐rhPSMA‐7 | 333 ± 44 MBq | —— |
| Giesel | 2018 | Germany | R | 251 | 70 (48–86) | 1.2 (0.2–228) | Siemens Biograph mCT | 18F-PSMA-1007 | 301 ± 46 MBq | —— |
| Rousseau | 2018 | Canada | P | 130 | 69.1 ± 6.5 | 5.20 ± 6.50 | GE Discovery PET/CT 600 or 690 | 18F-DCFPyL | 369.2 ± 47.2 MBq | —— |
| Wondergem | 2019 | Netherlands | R | 248 | 71 (67–75) | Philips Ingenuity TF, Siemens Biograph 16 | 18F-DCFPyL | 311 MBq | —— | |
| Mena | 2019 | USA | P | 90 | 66 (50–81) | 2.5 ± 5.9 | GE Discovery MI | 18F-DCFPyL | 299.9 ± 15.5 MBq | —— |
| Song | 2019 | USA | P | 72 | 71.5 ± 7.2 | 3.0 (0.23-698.4) | GE Discovery MI | 18F-DCFPyL | 338.8 ± 25.3 MBq | —— |
| Witkowska-Patena | 2019 | Poland | P | 40 | 68.6 ± 6.5 | 0.75 ± 0.6 | GE Discovery 710, | 18F-PSMA-1007 | 295.5 ± 14.1 MBq | —— |
| Rowe | 2020 | USA | P | 31 | 63 (45–74) | 0.4 (0.2–28.3) | GE Discovery RX 64 or Biograph mCT 128 | 18F-DCFPyL | <333 MBq | —— |
| Chaussé | 2020 | Canada | R | 93 | 70.4(51-87) | 2.27 (0.07–51.09) | GE Discovery ST | 18F-DCFPyL | 333 ± 37 MBq | Multiple |
| Dietlein | 2021 | Germany | R | 70 | 70.1 ± 5.5 | 18F-JK-PSMA-7 | 348 ± 55 MBq | —— | ||
| Koschel | 2021 | Australia | P | 98 | 68.0 (66.0–71.0) | 0.32 (0.28–0.36) | GE Discovery 710 | 18F-DCFPyL | 250 ± 50 MBq | Imaging |
| Perry | 2021 | New Zealand | R | 222 | 71 (49–89) | 0.51 (0.08–58.9) | GE Discovery 690, 710 | 18F-DCFPyL | 250 ± 50 MBq | —— |
A multiple reference standards including biopsy, other imaging modalities and follow-up.